| name | endo-testosterone-therapy-symptomatic-low-testosterone |
| description | Suggests testosterone therapy as symptomatically indicated for low testosterone levels, and not for improving dyslipidemia or cardiovascular disease risk. Trigger phrases include "Patient with low testosterone symptomatic", "Considering testosterone for hypogonadism symptoms", and "Assessing appropriate indications for testosterone replacement". |
Testosterone therapy as symptomatically indicated for low testosterone levels
STEP 1 — Gather Information
Confirm low total testosterone (<300 ng/dL) on two morning samples; assess for hypogonadism symptoms (low libido, erectile dysfunction, fatigue, decreased muscle mass, mood changes); screen for contraindications (prostate/breast cancer, untreated severe sleep apnea, hematocrit >54%).
→ Proceed to step 2 if low testosterone and symptoms are present.
STEP 2 — Rule In / Rule Out
Is the patient symptomatic for hypogonadism?
- Yes: Rule in testosterone therapy for symptom relief; proceed to step 3.
- No: Rule out testosterone therapy for lipid/CV risk reduction; do not initiate therapy.
→ Decision based on symptom presence.
STEP 3 — Classify or Stratify
Are there contraindications to testosterone therapy?
- No contraindications: Proceed to step 4.
- Contraindications present: Do not initiate testosterone therapy; address underlying condition or consider alternatives.
→ Decision based on safety assessment.
STEP 4 — Decide
If symptomatic low testosterone and no contraindications, suggest testosterone therapy (gel, injection, or patch) for symptom improvement; monitor efficacy and adverse effects at 3–6 months.
→ Initiate therapy or withhold based on benefit-risk assessment.
Clinical Guardrails / Mimics / Pitfalls
Do not use testosterone to improve dyslipidemia or reduce cardiovascular disease risk; avoid in prostate/breast cancer, uncontrolled severe sleep apnea, hematocrit >54%; monitor PSA, hematocrit, lipids, liver enzymes; discontinue if adverse effects occur or no symptom improvement.
Concrete Clinical Example
A 58-year-old man with total testosterone 260 ng/dL on two morning samples reports low libido and fatigue; after ruling out prostate cancer and sleep apnea, testosterone gel is initiated for symptom improvement.
Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Newman CB et al., 2020, doi:10.1210/clinem/dgaa674
